Predictors and Long-Term Outcomes of Pathological Complete Response Following Neoadjuvant Treatment and Radical Surgery for Locally Advanced Rectal Cancer
Journal of Clinical Medicine · 15.06.2025 · 14 (12) · 4251
DOI: 10.3390/jcm14124251 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 15.06.2025. Verfasst von Dan Assaf und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of General Surgery, Sheba Medical Center, Ramat Gan 5262000, Israel. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Pathological complete response (pCR) following neoadjuvant therapy and surgery for locally advanced rectal cancer is associated with improved prognosis. Accurately predicting who will achieve pCR could theoretically eliminate the need for surgery for these patients. We aimed to compare pCR and non-pCR rectal cancer patients following neoadjuvant therapy, searching for clinical predictors for pCR and comparing oncological outcomes between these groups.
Methods
This is a single-center retrospective analysis of all patients who underwent a curative-intent rectal resection between 2010 and 2020 for primary non-metastatic rectal cancer following neoadjuvant therapy. The cohort (263 patients) was divided into two groups according to the pathological results from surgery: the pCR group (53 patients) and the non-pCR group (210 patients).
Results
The groups were similar in terms of baseline characteristics, clinical presentation, and staging, but tumors of the pCR group were significantly higher in the rectum (mean distance from the anal verge 7.92 cm versus 6.9 cm respectively, p = 0.04), and more of them were located at the posterior rectal wall (37.7% versus 24.3%, p = 0.049). Multivariate analysis found posterior location and tumor height to be significantly associated with pCR (OR 2.23, 95% CI 1.11–4.45, p = 0.023), (OR 1.14, 95% CI 1.03–1.27, p = 0.015). The 5-year overall survival was 95.6% in the pCR group compared with 87.5% in the non-pCR group (p = 0.09), and the 5-year disease-free survival was 92.7% versus 64.5%, respectively (p < 0.001).
Conclusions
Tumor location at the posterior wall of the rectum and higher tumor location were found to be associated with pCR. Patients achieving pCR demonstrate improved prognosis compared with non-pCR patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of General Surgery, Sheba Medical Center, Ramat Gan 5262000, Israel.
- Department of Oncology, Sheba Medical Center, Ramat Gan 5262000, Israel.
- Faculty of Medicine, Tel-Aviv University, Tel-Aviv 6997801, Israel.
ORCID-Profile: Yaacov Lawrence, Michael Goldenshluger, Lior Segev
Zitieren
APA
Assaf, D., Lawrence, Y., Margalit, O., Shacham-Shmueli, E., Bear, L., Elbaz, N., Lebedayev, A., Ram, E., Anderson, Y., Gruper, O., Goldenshluger, M., & Segev, L. (2025). Predictors and Long-Term Outcomes of Pathological Complete Response Following Neoadjuvant Treatment and Radical Surgery for Locally Advanced Rectal Cancer. Journal of Clinical Medicine, 14(12), 4251. https://doi.org/10.3390/jcm14124251
Vancouver
Assaf D, Lawrence Y, Margalit O, Shacham-Shmueli E, Bear L, Elbaz N, et al. Predictors and Long-Term Outcomes of Pathological Complete Response Following Neoadjuvant Treatment and Radical Surgery for Locally Advanced Rectal Cancer. Journal of Clinical Medicine. 2025;14(12):4251. doi:10.3390/jcm14124251
BibTeX
@article{Assaf2025,
author = {Assaf, Dan and Lawrence, Yaacov and Margalit, Ofer and Shacham-Shmueli, Einat and Bear, Lior and Elbaz, Nadav and Lebedayev, Alexander and Ram, Edward and Anderson, Yasmin and Gruper, Ofir and Goldenshluger, Michael and Segev, Lior},
title = {Predictors and Long-Term Outcomes of Pathological Complete Response Following Neoadjuvant Treatment and Radical Surgery for Locally Advanced Rectal Cancer},
journal = {Journal of Clinical Medicine},
year = {2025},
volume = {14},
number = {12},
pages = {4251},
doi = {10.3390/jcm14124251}
}
EUVIMED